Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and Richter’s strategies.
Adam Kittai, MD
Advertisement
Adam Kittai, MD, is an Associate Professor of Medicine (Hematology and Medical Oncology) with a clinical research focus on non-Hodgkin lymphoma at Mount Sinai.
Articles by Adam Kittai, MD
Advertisement
Latest Updated Articles
Choosing Wisely in CLL: A Deep Dive Into Frontline TreatmentApril 15th 2026
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5